Antidepressants for cognitive impairment in schizophrenia - A systematic review and meta-analysis

Schizophrenia Research

Volumn 159, Issue 2-3, 2014, Pages 385-394

  Vernon, Jeffrey A ^a   Grudnikoff, Eugene ^b   Seidman, Andrew J ^b   Frazier, Thomas W ^c   Vemulapalli, Mani Sandhya ^d   Pareek, Priyanki ^a   Goldberg, Terry E ^b,e,f   Kane, John M ^b,e,f,g   Correll, Christoph U ^b,e,f,g  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha 2 antagonists; Antidepressants; Augmentation; Cognition; Cognitive impairment; Schizophrenia; Selective serotonin reuptake inhibitors

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DULOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AKATHISIA; ARTICLE; ATTENTION; CARDIOPULMONARY INSUFFICIENCY; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISEASE DURATION; DRUG WITHDRAWAL; DYSKINESIA; EFFECT SIZE; EXECUTIVE FUNCTION; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HUMAN; INSOMNIA; LONG TERM MEMORY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; RESPIRATORY TRACT DISEASE; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUICIDAL IDEATION; SYSTEMATIC REVIEW; VERBAL MEMORY; WEAKNESS; WORKING MEMORY; COGNITION DISORDERS; COMPLICATION; DRUG POTENTIATION; MIDDLE AGED;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 84916897771     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.08.015     Document Type: Article

References (66)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 2004, (Suppl. 1):S1-S5.
2. Albus M., Hubmann W., Mohr F., Hecht S., Hinterberger-Weber P., Seitz N.N., Küchenhoff H. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256(7):442-451.
3. Barr R.S., Culhane M.A., Jubelt L.E., Mufti R.S., Dyer M.A., Weiss A.P., Deckersbach T., Kelly J.F., Freudenreich O., Goff D.C., Evins A.E. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008, 33(3):480-490.
4. Berk M., Gama C.S., Sundram S., Hustig H., Koopowitz L., D'Souza R., Malloy H., Rowland C., Monkhouse A., Monkhouse A., Bole F., Sathiyamoorthy S., Piskulic D., Dodd S. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum. Psychopharmacol. 2009, 24:233-238.
5. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., Pappadopulos E., Willson D.F., Alvir J.M., Woerner M.G., Geisler S., Kane J.M., Lieberman J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 2000, 157(4):549-559.
6. Bloch B., Reshef A., Cohen T., Tafla A., Gathas S., Israel S., Gritsenko I., Kremer I., Ebstein R.P. Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. Psychiatry Res. 2010, 175(1-2):38-42.
7. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., Harvey P.D. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 2008, 63(5):505-511.
8. Bowie C.R., Depp C., McGrath J.A., Wolyniec P., Mausbach B.T., Thornquist M.H., Luke J., Patterson T.L., Harvey P.D., Pulver A.E. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010, 167(9):1116-1124.
9. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., Marder S.R. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31(1):5-19.
10. Caforio G., DiGiorgio A., Rampino A., Rizzo M., Romano R., Taurisano P., Fazio L., DeSimeis G., Ursini G., Blasi G., Nardini M., Mancini M., Bertolino A. Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia. J. Clin. Psychopharmacol. 2013, 33(6):810-812.
11. Cho S.J., Yook K., Kim B., Choi T.K., Lee K.S., Kim Y.W., Lee J.E., Suh S., Yook K.H., Lee S.H. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(1):208-211.
12. Choi K.H., Wykes T., Kurtz M.M. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br. J. Psychiatry 2013, 203:172-178.
13. Coyle J.T., Balu D., Benneyworth M., Basu A., Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin. Neurosci. 2010, 12(3):359-382.
14. Culhane M.A., Schoenfeld D.A., Barr R.S., Cather C., Deckersbach T., Freudenreich O., Goff D.C., Rigotti N.A., Evins A.E. Predictors of early abstinence in smokers with schizophrenia. J. Clin. Psychiatry 2008, 69:1743-1750.
15. Dawes S.E., Palmer B.W., Meeks T., Golshan S., Kasckow J., Mohamed S., Zisook S. Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?. Neuropsychobiology 2012, 65:168-172.
16. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7(3):177-188.
17. Evins A.E., Cather C., Deckersbach T., Freudenreich O., Culhane M.A., Olm-Shipman C.S., Henderson D.C., Schoenfeld D.A., Goff D.C., Rigotti N.A. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J. Clin. Psychopharmacol. 2005, 25:218-225.
18. Evins A.E., Deckersbach T., Cather C., Freudenreich O., Culhane M.A., Henderson D.C., Green M.F., Schoenfeld D.A., Rigotti N.A., Goff D.C. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J. Clin. Psychiatry 2005, 66:1184-1190.
19. Evins A.E., Cather C., Culhane M.A., Birnbaum A., Horowitz J., Hsieh E., Freudenreich O., Henderson D.C., Schoenfeld D.A., Rigotti N.A., Goff D.C. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J. Clin. Psychopharmacol. 2007, 27(4):380-386.
20. Foster D.J., Jones C.K., Conn P.J. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discov. Med. 2012, 14(79):413-420.
21. Friedman J.I., Ocampo R., Elbaz Z., Parrella M., White L., Bowler S., Davis K.L., Harvey P.D. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J. Clin. Psychopharmacol. 2005, 25(3):237-242.
22. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., Kosten T.R., Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26(1):75-85.
23. George T.P., Vessicchio J., Allen T., Weinberger A., Sacco K.A. A randomized, double-blind, placebo-controlled trial of sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia: neuropsychological predictors of treatment outcome. ACNP Annual Meeting 2006, S254-S255.
24. George T.P., Vessicchio J.C., Sacco K.A., Weinberger A.H., Dudas M.M., Allen T.M., Creeden C.L., Potenza M.N., Feingold A., Jatlow P.I. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol. Psychiatry 2008, 63:1092-1096.
25. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64(10):1115-1122.
26. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J. Clin. Psychiatry 2006, 67(Suppl. 9):3-8.
27. Green M.F., Kern R.S., Braff D.L. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
28. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72:41-51.
29. Harvey P.D., Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001, 158:176-184.
30. Hecht E.M., Landy D.C. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia: a meta-analysis. Schizophr. Res. 2011, 134(2-3):202-206.
31. Herman A.I., Sofuoglu M. Cognitive effects of nicotine: genetic moderators. Addict. Biol. 2010, 15(3):250-265.
32. Joffe G., Terevnikov V., Joffe M., Stenberg J.H., Burkin M., Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr. Res. 2009, 108:245-251.
33. Jones C.K., Byun N., Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012, 37(1):16-42.
34. Kane J.M., Lencz T. Cognitive deficits in schizophrenia: short-term and long-term. World Psychiatry 2008, 7(1):29-30.
35. Kasckow J., Lanouette N., Patterson T., Fellows I., Golshan S., Solorzano E., Zisook S. Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning. Int. J. Geriatr. Psychiatry 2010, 25:183-190.
36. Keefe R.S.E., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33(4):912-920.
37. Lee J.E., Cho S.J., Lee K.S., Yook K.H., Choe A.Y., Lee S., Kim B., Kim K.H., Choi T.K., Lee S.H. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: a preliminary randomized placebo-controlled trial. Clin. Psychopharmacol. Neurosci. 2011, 9(2):73-77.
38. Lencz T., Smith C.W., McLaughlin D. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry 2006, 59:863-871.
39. Lin C.H., Huang C.L., Chang Y.C., Chen P.W., Lin C.Y., Tsai G.E., Lane H.Y. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophr. Res. 2013, 146(1-3):231-237.
40. Lisman J., Yasuda R., Raghavachari S. Mechanisms of CaMKII action in long-term potentiation. Nat. Rev. Neurosci. 2012, 13(3):169-182.
41. Menniti F.S., Lindsley C.W., Conn P.J., Pandit J., Zagouras P., Volkmann R.A. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr. Top. Med. Chem. 2013, 13(1):26-54.
42. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23(3):315-336.
43. Micò U., Bruno A., Pandolfo G., Maria Romeo V., Mallamace D., D'Arrigo C., Spina E., Zoccali R.A., Muscatello M.R.A. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int. Clin. Psychopharmacol. 2011, 26(6):303-310.
44. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17(12):1206-1227.
45. Mohamed S., Paulsen J.S., O'Leary D., Arndt S., Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiatry 1999, 56(8):749-754.
46. Moss T.G., Sacco K.A., Allen T.M., Weinberger A.H., Vessicchio J.C., George T.P. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. 2009, 104:94-99.
47. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62(3):1574-1583.
48. Niitsu T., Fujisaki M., Shiina A., Yoshida T., Hasegawa T., Kanahara N., Hashimoto T., Shiraishi T., Fukami G., Nakazato M., Shirayama Y., Hashimoto K., Iyo M. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J. Clin. Psychopharmacol. 2012, 32(5):593-601.
49. Poyurovsky M., Koren D., Gonopolsky I., Schneidman M., Fuchs C., Weizman A., Weizman R. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 2003, 13:123-128.
50. Poyurovsky M., Fuchs C., Pashinian A., Levi A., Faragian S., Maayan R., Gil-Ad I. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) 2007, 192:441-448.
51. Poyurovsky M., Faragian S., Fuchs C., Pashinian A. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. Isr. J. Psychiatry Relat. Sci. 2009, 46(3):213-220.
52. Rummel C., Kissling W., Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst. Rev. 2006, 3:CD005581.
53. Sepehry A.A., Potvin S., Elie R., Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J. Clin. Psychiatry 2007, 68:604-610.
54. Singh S.P., Singh V., Kar N., Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 2010, 197:174-179.
55. Stenberg J.H., Terevnikov V., Joffe M., Tiihonen J., Tchoukhine E., Burkin M., Joffe G. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int. J. Neuropsychopharmacol. 2010, 13:433-441.
56. Terevnikov V., Stenberg J.H., Tiihonen J., Joffe M., Burkin M., Tchoukhine E., Joffe G. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. Hum. Psychopharmacol. 2011, 26:188-193.
57. Tsoi D.T., Porwal M., Webster A.C. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst. Rev. 2013, 2:CD007253.
58. Velligan D.I., Bow-Thomas C.C., Mahurin R.K., Miller A.L., Halgunseth L.C. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?. J. Nerv. Ment. Dis. 2000, 188(8):518-524.
59. Verdoux H., Liraud F., Assens F., Abalan F., van Os J. Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients. Schizophr. Res. 2002, 56:149-159.
60. Vohora D., Bhowmik M. Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. Front. Syst. Neurosci. 2012, 6(72):1-10.
61. Weiner E., Ball M.P., Buchholz A.S., Gold J.M., Evins A.E., McMahon R.P., Buchanan R.W. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J. Clin. Psychiatry 2012, 73(1):95-102.
62. Whitehead C., Moss S., Cardno A., Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol. Med. 2003, 33:589-599.
63. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168(5):472-485.
64. Zanelli J., Reichenberg A., Morgan K., Fearon P., Kravariti E., Dazzan P., Morgan C., Zanelli C., Demjaha A., Jones P.B., Doody G.A., Kapur S., Murray R.M. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am. J. Psychiatry 2010, 167(1):78-85.
65. Zisook S., Kasckow J.W., Golshan S., Fellows I., Solorzano E., Lehman D., Mohamed S., Jeste D.V. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J. Clin. Psychiatry 2009, 70(4):562-571.
66. Zisook S., Kasckow J.W., Lanouette N.M., Golshan S., Fellows I., Vahia I., Mohamed S., Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J. Clin. Psychiatry 2010, 71(7):915-922.